SEAT:NASDAQVivid Seats Inc. Analysis
Data as of 2026-07-18 - not real-time
$7.09
Latest Price
8/10Risk
Risk Level: High
Executive Summary
Vivid Seats is trading well beneath its short‑term and longer‑term moving averages, indicating a sustained price weakness. The relative strength index sits below the midpoint, suggesting neutral to slightly bearish momentum. A bullish MACD crossover provides a modest technical upside signal, yet the overall trend remains bearish. Trading volume has been contracting, reinforcing the downside pressure. Volatility is exceptionally high, making price swings unpredictable. The stock’s beta exceeds one, implying greater sensitivity to market moves. The price is close to a identified support level while still far from the next resistance barrier.
Fundamentally, revenue is contracting and margins are deep in the red, reflecting an unprofitable business model. Operating cash flow and free cash flow are negative, and the company carries a sizable debt load relative to its cash reserves. Book value per share is negative, and traditional valuation multiples such as PE and PB are nonsensical. Despite these challenges, the price‑to‑sales multiple is very low, hinting at a potential upside. Analyst price targets suggest a sizable upside, though consensus recommendations are absent. The firm does not pay a dividend, eliminating any income component for investors. In sum, the stock sits at a crossroads of technical uncertainty and fundamental distress, requiring careful risk consideration.
Fundamentally, revenue is contracting and margins are deep in the red, reflecting an unprofitable business model. Operating cash flow and free cash flow are negative, and the company carries a sizable debt load relative to its cash reserves. Book value per share is negative, and traditional valuation multiples such as PE and PB are nonsensical. Despite these challenges, the price‑to‑sales multiple is very low, hinting at a potential upside. Analyst price targets suggest a sizable upside, though consensus recommendations are absent. The firm does not pay a dividend, eliminating any income component for investors. In sum, the stock sits at a crossroads of technical uncertainty and fundamental distress, requiring careful risk consideration.
Market Outlook
Short Term
< 1 yearCautious
Model confidence: 7/10
Key Factors
- bearish price trend
- decreasing trading volume
- negative earnings and cash flow
Medium Term
1–3 yearsNeutral
Model confidence: 5/10
Key Factors
- potential upside indicated by low price‑to‑sales
- bullish MACD signal
- ongoing fundamental weakness
Long Term
> 3 yearsPositive
Model confidence: 6/10
Key Factors
- significant upside potential from analyst targets
- platform growth opportunities in ticket marketplace
- low valuation multiples relative to sales
Key Metrics & Analysis
Financial Health
Revenue Growth-23.30%
Profit Margin-82.25%
P/E Ratio-1.9
ROE-284.31%
ROA-3.32%
P/B Ratio-0.8
Op. Cash Flow$-20304000
Free Cash Flow$-10885250
Industry P/E16.1
Technical Analysis
TrendBearish
RSI46.3
Support$5.88
Resistance$8.68
MA 20$7.11
MA 50$7.94
MA 200$8.03
MACDBullish
VolumeDecreasing
Fear & Greed Index87.91
Valuation
Target Price$10.37
Upside/Downside46.24%
GradeUndervalued
TypeGrowth
Risk Assessment
Beta1.47
Volatility88.52%
Sector RiskMedium
Reg. RiskLow
Geo RiskMedium
Currency RiskLow
Liquidity RiskHigh
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.